Healthcare Brief Comoros: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Brief Comoros.

Press releases published on October 29, 2026

Oct. 29, 2026

RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call

Indeterminate GlobeNewswire

Oct. 29, 2026

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

Indeterminate GlobeNewswire

Oct. 29, 2026

American Stallion Expands Into Physician-Led Telehealth and Men’s Health Services

Indeterminate GlobeNewswire

Oct. 29, 2026

Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform

Indeterminate GlobeNewswire

Oct. 29, 2026

Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis

Indeterminate GlobeNewswire

Oct. 29, 2026

ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline

Indeterminate GlobeNewswire

Oct. 29, 2026

Cardiolyse führt KI-gestützten ECG Workspace ein: 12-Kanal-EKG-Befundung von der Erstauswertung bis zur ärztlichen Freigabe

Indeterminate GlobeNewswire

Oct. 29, 2026

Cardiolyse Launches AI-Powered ECG Workspace for 12-Lead ECG Review from First Read to Clinician Sign-Off

Indeterminate GlobeNewswire

Oct. 29, 2026

Cardiolyse lance ECG Workspace : l’analyse des ECG à 12 dérivations assistée par l’IA, de la première lecture à la validation médicale

Indeterminate GlobeNewswire

Oct. 29, 2026

Cardiolyse lancia ECG Workspace: refertazione degli ECG a 12 derivazioni assistita dall’IA, dalla prima lettura alla validazione medica

Indeterminate GlobeNewswire

Oct. 29, 2026

ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES

Indeterminate GlobeNewswire

Oct. 29, 2026

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

Indeterminate GlobeNewswire

Oct. 29, 2026

Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)

Indeterminate GlobeNewswire

Oct. 29, 2026

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

Indeterminate GlobeNewswire